Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Casirivimab/imdevimab  COVID-19 treatment studies for Casirivimab/i..  C19 studies: Casirivimab/i..  Casirivimab/i..   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Death/hospitalization 60% Improvement Relative Risk c19early.org/r Hussein et al. Casirivimab/i.. for COVID-19 EARLY Favors casirivimab/im.. Favors control
Real-world effectiveness of casirivimab and imdevimab among patients diagnosed with COVID-19 in the ambulatory setting: a retrospective cohort study using a large claims database
Hussein et al., BMJ Open, doi:10.1136/bmjopen-2022-064953
Hussein et al., Real-world effectiveness of casirivimab and imdevimab among patients diagnosed with COVID-19 in the ambulatory.., BMJ Open, doi:10.1136/bmjopen-2022-064953
Dec 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 73,759 outpatients treated with casirivimab/imdevimab, showing lower mortality with treatment. This result is subject to potentially substantial confounding by indication - patients with more severe cases may be more likely to receive treatment, and severity information was unavailable in the database.
Efficacy is variant dependent. In Vitro research suggests a lack of efficacy for omicron [Liu, Sheward, Tatham, VanBlargan]. This study is excluded in the after exclusion results of meta analysis: substantial unadjusted confounding by indication possible.
risk of death/hospitalization, 60.0% lower, HR 0.40, p < 0.001, NNT 35, propensity score matching, Cox proportional hazards, day 30.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Hussein et al., 19 Dec 2022, retrospective, USA, peer-reviewed, 9 authors, study period 1 December, 2020 - 30 September, 2021.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperCasirivimab/i..All
Abstract: Original research Real-­world effectiveness of casirivimab and imdevimab among patients diagnosed with COVID-­19 in the ambulatory setting: a retrospective cohort study using a large claims database Mohamed Hussein ‍ ‍, Wenhui Wei, Vera Mastey, Robert J Sanchez, Degang Wang, Dana J Murdock, Boaz Hirshberg, David M Weinreich, Jessica J Jalbert To cite: Hussein M, Wei W, Mastey V, et al. Real-­world effectiveness of casirivimab and imdevimab among patients diagnosed with COVID-­19 in the ambulatory setting: a retrospective cohort study using a large claims database. BMJ Open 2022;12:e064953. doi:10.1136/ bmjopen-2022-064953 ► Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (http://dx.doi.org/10.1136/​ bmjopen-2022-064953). Received 19 May 2022 Accepted 28 November 2022 © Author(s) (or their employer(s)) 2022. Re-­use permitted under CC BY-­NC. No commercial re-­use. See rights and permissions. Published by BMJ. Regeneron Pharmaceuticals Inc, Tarrytown, New York, USA Correspondence to Dr Mohamed Hussein; ​mohamed.​hussein@r​ egeneron.​ com ABSTRACT Objective To assess the real-­world effectiveness of casirivimab and imdevimab (CAS+IMD) versus no COVID-­19 antibody treatment among patients diagnosed with COVID-­19 in the ambulatory setting, including patients diagnosed during the Delta-­dominant period prior to Omicron emergence. Design Retrospective cohort study. Setting Komodo Health closed claims database. Participants 13 273 128 patients diagnosed with COVID-­19 (December 2020 through September 2021) were treated with CAS+IMD or untreated but treatment eligible under the Emergency Use Authorization (EUA). Each treated patient was exact and propensity score matched without replacement to up to five untreated EUA-­eligible patients. Interventions CAS+IMD. Primary and secondary outcome measures Composite endpoint of 30-­day all-­cause mortality or COVID-­19-­ related hospitalisation. Kaplan-­Meier estimators were used to calculate outcome risks overall and across subgroups: age, COVID-­19 vaccination status, immunocompromised status, and timing of diagnosis (December 2020 to June 2021, and July to September 2021). Cox proportional hazards models were used to estimate adjusted HRs (aHRs) and 95% CIs. Results Among 75 159 CAS+IMD-­treated and 1 670 338 EUA-­eligible untreated patients, 73 759 treated patients were matched to 310 688 untreated patients; matched patients were ~50 years, ~60% were women and generally well balanced across risk factors. The 30-­day risk of the composite outcome was 2.1% and 5.2% in the CAS+IMD-­treated and CAS+IMD-­untreated patients, respectively; equivalent to a 60% lower risk (aHR 0.40; 95% CI, 0.38 to 0.42). The effect of CAS+IMD was consistent across subgroups, including those who received a COVID-­19 vaccine (aHR 0.48, 95% CI, 0.41 to 0.56), and those diagnosed during the Delta-­dominant period (aHR 0.40, 95% CI, 0.38 to 0.42). Conclusions The real-­world effectiveness of CAS+IMD is consistent with the efficacy for reducing all-­cause mortality or COVID-­19-­related hospitalisation reported STRENGTHS AND LIMITATIONS OF THIS STUDY ⇒ This retrospective cohort study assessed the real-­ world effectiveness of casirivimab and imdevimab (CAS+IMD) versus no COVID-­19 antibody treatment among patients diagnosed with COVID-­19 in the ambulatory setting, including patients diagnosed during the Delta-­dominant..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit